MX2019015273A - Moduladores de alfa-sinucleinca. - Google Patents

Moduladores de alfa-sinucleinca.

Info

Publication number
MX2019015273A
MX2019015273A MX2019015273A MX2019015273A MX2019015273A MX 2019015273 A MX2019015273 A MX 2019015273A MX 2019015273 A MX2019015273 A MX 2019015273A MX 2019015273 A MX2019015273 A MX 2019015273A MX 2019015273 A MX2019015273 A MX 2019015273A
Authority
MX
Mexico
Prior art keywords
alpha
synuclein
modulators
treatment
conditions
Prior art date
Application number
MX2019015273A
Other languages
English (en)
Inventor
Jae Moon Lee
Eunhee Kim
Taeik Jang
Boksuk Kim
Changsun Yu
Sungeun Yoo
Yeontae Chung
Original Assignee
Kainos Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kainos Medicine Inc filed Critical Kainos Medicine Inc
Publication of MX2019015273A publication Critical patent/MX2019015273A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Abstract

La descripción proporciona métodos diagnósticos y métodos para el tratamiento de afecciones derivadas de alfa-sinucleinopatías. Un compuesto de aminopirazol se puede utilizar para el tratamiento de tales afecciones disminuyendo la cantidad de alfa-sinucleína en células de un sujeto.
MX2019015273A 2017-06-19 2018-06-19 Moduladores de alfa-sinucleinca. MX2019015273A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762521758P 2017-06-19 2017-06-19
PCT/IB2018/000766 WO2018234864A2 (en) 2017-06-19 2018-06-19 ALPHA-SYNUCLEINE MODULATORS

Publications (1)

Publication Number Publication Date
MX2019015273A true MX2019015273A (es) 2020-08-17

Family

ID=64736960

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015273A MX2019015273A (es) 2017-06-19 2018-06-19 Moduladores de alfa-sinucleinca.

Country Status (12)

Country Link
US (1) US20200206191A1 (es)
EP (1) EP3641761A4 (es)
JP (2) JP2020524667A (es)
KR (1) KR20200010487A (es)
CN (1) CN110891565A (es)
AU (1) AU2018287319A1 (es)
BR (1) BR112019027029A2 (es)
CA (1) CA3067135A1 (es)
IL (1) IL271359B2 (es)
MX (1) MX2019015273A (es)
SG (1) SG11201911313YA (es)
WO (1) WO2018234864A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102150377B1 (ko) * 2020-03-26 2020-09-01 서울대학교산학협력단 플루오린-18이 치환된 피라졸 유도체 방사성의약품 제조방법
CN115989029A (zh) * 2020-08-25 2023-04-18 国立研究开发法人量子科学技术研究开发机构 新化合物、α突触核蛋白凝集体结合剂及其利用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
KR100832747B1 (ko) * 2006-10-27 2008-05-27 한국화학연구원 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물
ES2392862B1 (es) * 2011-06-02 2013-11-05 Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal Tgf-beta y/o smad3 como marcadores de diagnóstico y/o pronóstico de alfa-sinucleinopatías
US20160007893A1 (en) * 2013-02-06 2016-01-14 Loxbridge Research Llp Systems and methods for early disease detection and real-time disease monitoring
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
KR20200127999A (ko) * 2018-01-30 2020-11-11 (주)카이노스메드 유기 화합물의 염 형성

Also Published As

Publication number Publication date
EP3641761A4 (en) 2021-03-24
WO2018234864A3 (en) 2019-02-14
RU2020101482A (ru) 2021-07-20
IL271359B1 (en) 2023-07-01
BR112019027029A2 (pt) 2020-07-14
CA3067135A1 (en) 2018-12-27
IL271359A (en) 2020-01-30
EP3641761A2 (en) 2020-04-29
WO2018234864A2 (en) 2018-12-27
SG11201911313YA (en) 2020-01-30
AU2018287319A1 (en) 2020-02-06
JP2023118923A (ja) 2023-08-25
US20200206191A1 (en) 2020-07-02
JP2020524667A (ja) 2020-08-20
IL271359B2 (en) 2023-11-01
KR20200010487A (ko) 2020-01-30
CN110891565A (zh) 2020-03-17
RU2020101482A3 (es) 2022-01-31

Similar Documents

Publication Publication Date Title
MY191169A (en) Anti-fcrh5 antibodies
NZ731467A (en) Anti-tim3 antibodies and methods of use
NZ765695A (en) Immune cell organoid co-cultures
MX2022014331A (es) Metodos y composiciones para el tratamiento de trastornos epilepticos.
MX2021004007A (es) Moduladores de linfocitos t reguladores multivalentes.
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MY188799A (en) Anti-cd79b antibodies and methods of use
PH12016501435A1 (en) Anti-jagged1 antibodies and methods of use
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
PH12016502167A1 (en) Hdl theraphy markers
SG10201804505VA (en) Near-infrared fluorescent contrast bioimaging agents and methods of use thereof
PH12019501373A1 (en) Methods of treating cochlears synaptopathy
MX2016010880A (es) Administracion de cuenta y fondo.
MY197758A (en) Methods for treating conditions associated with masp-2 dependent complement activation
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
GB2548277A (en) Antibiofilm compositions
IL282447A (en) Methods and preparations for healing eye cell
MY193650A (en) Extracellular matrix compositions
PH12017501864A1 (en) Compositions and methods for treating autism
PH12020550185A1 (en) Semaglutide in medical therapy
SG10201810016XA (en) Methods of treating depression using nmda modulators
MX2019015273A (es) Moduladores de alfa-sinucleinca.